Cargando…

Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers

There are currently no effective targeted therapies for KRAS mutant cancers. Therapeutic strategies that combine MEK inhibitors with agents that target apoptotic pathways may be a promising therapeutic approach. We investigated combining MEK and MDM2 inhibitors as a potential treatment strategy for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hata, Aaron N, Rowley, Steve, Archibald, Hannah L, Gomez-Caraballo, Maria, Siddiqui, Faria M, Ji, Fei, Jung, Joonil, Light, Madelyn, Lee, Joon Sang, Debussche, Laurent, Sidhu, Sukhvinder, Sadreyev, Ruslan I, Watters, James, Engelman, Jeffrey A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700857/ https://www.ncbi.nlm.nih.gov/pubmed/28783173 http://dx.doi.org/10.1038/onc.2017.258

Ejemplares similares

Enhanced G1 arrest and apoptosis via MDM4/MDM2 double knockdown and MEK inhibition in wild-type TP53 colon and gastric cancer cells with aberrant KRAS signaling
por: Wang, Xiaoxuan, et al.
Publicado: (2021)

Synergistic effect of the inhibitors of RAF/MEK and AXL on KRAS‐mutated ovarian cancer cells with high AXL expression
por: Umemura, Shiori, et al.
Publicado: (2020)

In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part III
por: Witkowski, Jakub, et al.
Publicado: (2023)

In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part II
por: Witkowski, Jakub, et al.
Publicado: (2022)

In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part I
por: Witkowski, Jakub, et al.
Publicado: (2022)

TEAD Inhibitors Sensitize KRAS(G12C) Inhibitors via Dual Cell Cycle Arrest in KRAS(G12C)-Mutant NSCLC
por: Tammaccaro, Salvina Laura, et al.
Publicado: (2023)

Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines
por: Ma, Yixuan, et al.
Publicado: (2022)

Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment
por: Hoffman-Luca, C. Gianna, et al.
Publicado: (2015)

KRAS-MEK Signaling Controls Ago2 Sorting into Exosomes
por: McKenzie, Andrew J., et al.
Publicado: (2016)

TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma
por: Jung, Joonil, et al.
Publicado: (2016)

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
por: Corcoran, Ryan B., et al.
Publicado: (2011)

MEK inhibition suppresses metastatic progression of KRAS‐mutated gastric cancer
por: Yamasaki, Juntaro, et al.
Publicado: (2022)

CRISPR/Cas9 Edited RAS & MEK Mutant Cells Acquire BRAF and MEK Inhibitor Resistance with MEK1 Q56P Restoring Sensitivity to MEK/BRAF Inhibitor Combo and KRAS G13D Gaining Sensitivity to Immunotherapy
por: Turner, Elizabeth, et al.
Publicado: (2022)

Lymphatic disorders caused by mosaic, activating KRAS variants respond to MEK inhibition
por: Sheppard, Sarah E., et al.
Publicado: (2023)

Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation
por: Lyons, Yasmin A., et al.
Publicado: (2014)

Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer
por: Kitai, Hidenori, et al.
Publicado: (2016)

KRAS and NRAS Translation Is Increased upon MEK Inhibitors-Induced Processing Bodies Dissolution
por: Vidal-Cruchez, Olivia, et al.
Publicado: (2023)

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
por: Laroche-Clary, Audrey, et al.
Publicado: (2017)

KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer
por: Nakayama, N, et al.
Publicado: (2008)

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
por: Temraz, Sally, et al.
Publicado: (2015)

Targeting wild-type KRAS amplified gastroesophageal cancer through combined MEK and SHP2
por: Wong, Gabrielle S., et al.
Publicado: (2018)

The oncogene KRAS promotes cancer cell dissemination by stabilizing spheroid formation via the MEK pathway
por: Ogishima, Juri, et al.
Publicado: (2018)

Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer
por: Wagner, Steve, et al.
Publicado: (2018)

Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors
por: Bhatt, Vrushank, et al.
Publicado: (2023)

Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer
por: Feng, Juanjuan, et al.
Publicado: (2023)

Synergistic inhibition of MEK and reciprocal feedback networks for targeted intervention in malignancy
por: Li, Yanan, et al.
Publicado: (2019)

Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS(G12R)-mutant pancreatic ductal adenocarcinoma
por: Kenney, Cara, et al.
Publicado: (2021)

Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells
por: Cheon, Seul‐Ki, et al.
Publicado: (2018)

Correction: Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer
por: Wagner, Steve, et al.
Publicado: (2019)

CUX1 Enhances Pancreatic Cancer Formation by Synergizing with KRAS and Inducing MEK/ERK-Dependent Proliferation
por: Griesmann, Heidi, et al.
Publicado: (2021)

Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss
por: Erasimus, Hélène, et al.
Publicado: (2023)

The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia
por: Seipel, Katja, et al.
Publicado: (2018)

Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists
por: Urso, Loredana, et al.
Publicado: (2017)

Synergistic effects of BET and MEK inhibitors promote regression of anaplastic thyroid tumors
por: Zhu, Xuguang, et al.
Publicado: (2018)

Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway
por: Conti, Annalisa, et al.
Publicado: (2015)

A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells
por: Ischenko, Irene, et al.
Publicado: (2015)

Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models
por: Lee, Michael S., et al.
Publicado: (2016)

A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC
por: Dompe, Nicholas, et al.
Publicado: (2018)

Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer
por: Choi, Hyejin, et al.
Publicado: (2019)

Targeting β-catenin overcomes MEK inhibition resistance in colon cancer with KRAS and PIK3CA mutations
por: Moon, Jai-Hee, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_reuu3ep4b4prv3o2h6g4fi19jn